PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24307657-3	2014	This study aimed to test whether overexpression of IL-6 and constitutive activation of Stat3 in prostate cancer cells increase resistance to enzalutamide.	enzalutamide	141-153	interleukin 6	Homo sapiens	51-55	
34204596-10	2021	IL-6 is implicated in resistance to enzalutamide.	enzalutamide	36-48	interleukin 6	Homo sapiens	0-4	
25970160-1	2015	PURPOSE: It is known that over expression of IL6 in prostate cancer cells confer enzalutamide resistance and that this may occur through constitutive Stat3 activation.	enzalutamide	81-93	interleukin 6	Homo sapiens	45-48	
25970160-10	2015	Knock down of Stat3 abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in prostate cancer cells expressing IL6.	enzalutamide	30-42	interleukin 6	Homo sapiens	149-152	
25970160-12	2015	CONCLUSIONS: This study demonstrated the IL6-Stat3-AR axis in prostate cancer is one of the crucial mechanisms of enzalutamide resistance.	enzalutamide	114-126	interleukin 6	Homo sapiens	41-44	
25970160-13	2015	Niclosamide has the potential to target the IL6-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced prostate cancer.	enzalutamide	77-89	interleukin 6	Homo sapiens	44-47	
24307657-8	2014	RESULTS: Prostate cancer cells expressing autocrine IL-6 are resistant to enzalutamide and autocrine IL-6 leads to constitutive activation of Stat3 and its target genes.	enzalutamide	74-86	interleukin 6	Homo sapiens	52-56	
24307657-13	2014	CONCLUSIONS: This study demonstrates that the autocrine IL-6 pathway induces enzalutamide resistance in prostate cancer cells via the constitutive activation of Stat3.	enzalutamide	77-89	interleukin 6	Homo sapiens	56-60	
24307657-14	2014	Co-targeting IL6-Stat3 pathway with enzalutamide may be utilized for treatment of advanced prostate cancer.	enzalutamide	36-48	interleukin 6	Homo sapiens	13-16